The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet Disease and their association with thrombosis

Thrombosis Research

Volumn 126, Issue 3, 2010, Pages 207-210

  Donmez, Ayhan ^a   Aksu, Kenan ^a   Aydin, Hakan ^a   Keser, Gokhan ^a   Cagirgan, Seckin ^a   Doganavsargil, Eker ^a   Tombuloglu, Murat ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Activated thrombin activatable fibrinolysis inhibitor; Beh et disease; Thrombomodulin; Thrombosis

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS;

ADULT; BEHCET SYNDROME; BIOLOGICAL MARKERS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOMODULIN; THROMBOSIS; TURKEY;

EID: 77956262525     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.05.019     Document Type: Article

References (33)

1. S. Yurdakul, and H. Yazici Behçet's syndrome Best Pract Res Clin Rheumatol 22 2008 793 803
2. Y. Koc, I. Gullu, G. Akpek, T. Akpolat, E. Kansu, and S. Kiraz Vascular involvement in Behçet's disease J Rheumatol 19 1992 402 410
3. P. Ames, A. Steuer, A. Pap, and A. Denman Thrombosis in Behçet's disease: a retrospective survey from a single UK centre Rheumatology 40 2001 652 655
4. I.C. Haznedaroglu, O.I. Ozcebe, O. Ozdemir, I. Celik, S.V. Dundar, and S. Kirazli Impaired haemostatic kinetics and endothelial function in Behçet's disease J Intern Med 240 1996 181 187
5. J.C. Chambers, D.O. Haskard, and J.S. Kooner Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome J Am Coll Cardiol 37 2001 517 520
6. S. Kiraz, I. Ertenli, M. Calguneri, M.A. Ozturk, I.C. Haznedaroglu, and B. Altun Interactions of nitric oxide and superoxide dismutase in Behçet's disease Clin Exp Rheumatol 19 Suppl24 2001 25 29
7. K. Aksu, N. Turgan, F. Oksel, G. Keser, D. Ozmen, and G. Kitapcioglu Hyperhomocysteinaemia in Behcet's disease Rheumatology 40 6 2001 687 690
8. S. Kiraz, I. Ertenli, M. Ozturk, I.C. Haznedaroglu, I. Celik, and M. Calguneri Pathological haemostasis and 'prothrombotic state' in Behçet's disease Thromb Res 105 2002 125 133
9. A.F. Oner, A. Gurgey, A. Gurler, and L. Mesci Factor V Leiden mutation in patients with Behçet's disease J Rheumatol 25 1998 496 498
10. P.B. Toydemir, A.H. Elhan, A. Tukun, R. Toydemir, A. Gurler, and A. Tuzuner Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Behçet's disease J Rheumatol 27 2000 2849 2854
11. H. Mishima, K. Masuda, S. Shimada, N. Toki, H. Tsushima, and M. Gocho Plasminogen activator activity levels in patients with Behçet's syndrome Arch Ophthalmol 103 1985 935 936
12. I.C. Haznedaroglu, I. Celik, Y. Buyukasik, A. Kosar, S. Kirazli, and S.V. Dundar Haemostasis, thrombosis, and endothelium in Behçet's disease Acta Haematol 99 1998 236 237
13. B.N. Bouma, and J.C. Meijers Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) J Thromb Haemost 1 2003 1566 1574
14. M.B. Boffa, M.E. Nesheim, and M.L. Koschinsky Thrombin Activable Fibrinolysis Inhibitor (TAFI): Molecular Genetics of an Emerging Potential Risk Factor for Thrombotic Disorders Curr Drug Targets Cardiovasc Haematol Disord 1 2001 59 74
15. N.H. Van Tilburg, F.R. Rosendaal, and R.M. Bertina Thrombin Activable Fibrinolysis Inhibitor and the risk for deep vein thrombosis Blood 95 2000 2855 2859
16. L. Bajzar, J. Morser, and M. Nesheim TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex J Biol Chem 271 1996 16603 16608
17. A. Donmez, K. Aksu, H.A. Celik, G. Keser, S. Cagirgan, and S.B. Omay Thrombin activatable fibrinolysis inhibitor in Behcet's disease Thromb Res 115 4 2005 287 292
18. M.A. Ozcan, S. Akar, I. Alacacioglu, O. Piskin, F. Yüksel, and O. Gurler Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease Turk J Med Sci 37 2007 267 271
19. J.M. Ricart, L.A. Ramon, A. Vaya, F. Espana, M.L. Santaolaria, and J. TodolI Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis Br J Haematol 141 5 2008 716 719
20. International Study Group for Behçet's Disease Evaluation of diagnostics ('classification') criteria in Behçet's disease-towards internationally agreed criteria Br J Rheumatol 31 1992 299 308
21. I. Krause, R. Mader, J. Sulkes, M. Paul, Y. Uziel, and M. Adawi Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity J Rheumatol 28 2001 1033 1036
22. N. Duzgun, E. Ayaslioglu, H. Tutkak, M. Sahin, O. Aydintug, and U. Olmez Plasma thrombomodulin levels in patients with Behçet's disease Rheumatol Int 23 2003 130 133
23. I.C. Haznedaroglu, O. Ozdemir, O. Ozcebe, S.V. Dundar, and S. Kirazli Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease Thromb Haemost 75 1996 974 975
24. O. Ozcebe, I.C. Haznedaroglu, O. Ozdemir, N.M. Sayinalp, S.V. Dundar, and S. Kirazli Soluble thrombomodulin and fibrinolysis in Behçet's disease Med Princ Pract 5 1996 146 150
25. G. Espinosa, J. Font, D. Tossies, A. Vidaller, R. Deulofeu, and A. Lopez-Soto Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation and thrombomodulin Am J Med 112 2002 37 43
26. A. Gurgey, A. Gurler, A.F. Oner, L. Mesci, and S. Kirazli Thrombomodulin levels in Behçet's disease with and without factor Leiden mutation Clin Rheumatol 17 1998 186 188
27. S. Demirer, N. Sengul, M.A. Yerdel, A. Tuzuner, A.T. Ulus, and A. Gurler Haemostasis in patients with Behçet's disease Eur J Vasc Endovasc Surg 19 2000 570 574
28. S. Navarro, J.M. Ricart, P. Medina, A. Vaya, P. Villa, and J. TodolI Activated protein C levels in Behçet's disease and risk of venous thrombosis Br J Haematol 125 4 2004 550 556
29. S. Takano, S. Kimura, S. Ohdama, and N. Aoki Plasma thrombomodulin in health and diseases Blood 76 1990 2024 2029
30. S. Odhama, S. Takano, S. Miyake, T. Kubato, K. Sato, and N. Aoki Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases Am J Clin Pathol 101 1994 109 113
31. L. Kotajima, S. Aotsuka, and T. Sato Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases Clin Exp Rheumatol 15 1997 59 65
32. M. KayIkcIoglu, K. Aksu, C. Hasdemir, G. Keser, N. Turgan, and H. Kultursay Endothelial functions in Behçet's disease Rheumatol Int 26 2006 304 308
33. A. Gul, U. Ozbek, C. Ozturk, M. Inanc, M. Konice, and T. Ozcelik Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease Br J Rheumatol 35 1996 1178 1180